Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838981 · ClinicalTrials.gov registry record · Phase 1
Pharmacotherapy & CM for Opioid and Cocaine Dependence
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT00838981: Completed Phase 1 study, sponsored by Yale University.
NCT00838981 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 91 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00838981, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of the combined treatment modafinil + Contingency Management (CM) to either treatment condition alone or to yoked-controls on cocaine abstinence. To investigate the role of modafinil-related improvements in memory, impulse control, and attention in mediating cocaine abstinence.
Primary Outcome
thrice weekly urine tests
Interventions
- DRUG Methadone
- BEHAVIORAL Contingency Management
- DRUG Modafinil
- DRUG Sugar Pill
- BEHAVIORAL cognitive behavioral treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT00838981 record still lists
NCT00838981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 5 interventions - of which Methadone is the first listed.
NCT00838981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00838981 about?
NCT00838981 is a clinical study titled "Pharmacotherapy & CM for Opioid and Cocaine Dependence". The purpose of this study is to compare the efficacy of the combined treatment modafinil + Contingency Management (CM) to either treatment condition alone or to yoked-controls on cocaine abstinence. To investigate the role of modafinil-related improvements in memory, impulse control, and attention ...
What is the current status of trial NCT00838981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2008-05. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00838981?
The interventions under investigation include: Methadone (DRUG), Contingency Management (BEHAVIORAL), Modafinil (DRUG), Sugar Pill (DRUG), cognitive behavioral treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00838981?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00838981's enrollment target sits among peer trials
91 626th of 2000 higher than 1,373 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia